Home > Research > Publications & Outputs > Investigation of TSPO variants in schizophrenia...

Research

Associated organisational units

Links

Text available via DOI:

Keywords

View graph of relations

Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. / Pouget, Jennie G.; Gonçalves, Vanessa F.; Nurmi, Erika L. et al.
In: Pharmacogenomics, Vol. 16, No. 1, 01.2015, p. 5-22.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Pouget, JG, Gonçalves, VF, Nurmi, EL, Laughlin, CP, Mallya, KS, McCracken, JT, Aman, MG, McDougle, CJ, Scahill, L, Misener, VL, Tiwari, AK, Zai, CC, Brandl, EJ, Felsky, D, Leung, AQ, Lieberman, JA, Meltzer, HY, Potkin, SG, Niedling, C, Steimer, W, Leucht, S, Knight, J, Müller, DJ & Kennedy, JL 2015, 'Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes', Pharmacogenomics, vol. 16, no. 1, pp. 5-22. https://doi.org/10.2217/pgs.14.158

APA

Pouget, J. G., Gonçalves, V. F., Nurmi, E. L., Laughlin, C. P., Mallya, K. S., McCracken, J. T., Aman, M. G., McDougle, C. J., Scahill, L., Misener, V. L., Tiwari, A. K., Zai, C. C., Brandl, E. J., Felsky, D., Leung, A. Q., Lieberman, J. A., Meltzer, H. Y., Potkin, S. G., Niedling, C., ... Kennedy, J. L. (2015). Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics, 16(1), 5-22. https://doi.org/10.2217/pgs.14.158

Vancouver

Pouget JG, Gonçalves VF, Nurmi EL, Laughlin CP, Mallya KS, McCracken JT et al. Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics. 2015 Jan;16(1):5-22. doi: 10.2217/pgs.14.158

Author

Pouget, Jennie G. ; Gonçalves, Vanessa F. ; Nurmi, Erika L. et al. / Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. In: Pharmacogenomics. 2015 ; Vol. 16, No. 1. pp. 5-22.

Bibtex

@article{dd645db604d04436b1df30332de53286,
title = "Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes",
abstract = "AIM: TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain.PATIENTS & METHODS: We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119).RESULTS: TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10(-3)), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10(-3)) and RUPP samples (p = 2.76 × 10(-4)).CONCLUSION: Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect.",
keywords = "Adolescent, Adult, Antipsychotic Agents, Female, Genetic Association Studies, Humans, Male, Middle Aged, Receptors, GABA, Schizophrenia, Treatment Outcome, Weight Gain",
author = "Pouget, {Jennie G.} and Gon{\c c}alves, {Vanessa F.} and Nurmi, {Erika L.} and Laughlin, {Christopher P.} and Mallya, {Karyn S.} and McCracken, {James T.} and Aman, {Michael G.} and McDougle, {Christopher J.} and Lawrence Scahill and Misener, {Virginia L.} and Tiwari, {Arun K.} and Zai, {Clement C.} and Brandl, {Eva J.} and Daniel Felsky and Leung, {Amy Q.} and Lieberman, {Jeffrey A.} and Meltzer, {Herbert Y.} and Potkin, {Steven G.} and Charlotte Niedling and Werner Steimer and Stefan Leucht and Jo Knight and M{\"u}ller, {Daniel J.} and Kennedy, {James L.}",
year = "2015",
month = jan,
doi = "10.2217/pgs.14.158",
language = "English",
volume = "16",
pages = "5--22",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes

AU - Pouget, Jennie G.

AU - Gonçalves, Vanessa F.

AU - Nurmi, Erika L.

AU - Laughlin, Christopher P.

AU - Mallya, Karyn S.

AU - McCracken, James T.

AU - Aman, Michael G.

AU - McDougle, Christopher J.

AU - Scahill, Lawrence

AU - Misener, Virginia L.

AU - Tiwari, Arun K.

AU - Zai, Clement C.

AU - Brandl, Eva J.

AU - Felsky, Daniel

AU - Leung, Amy Q.

AU - Lieberman, Jeffrey A.

AU - Meltzer, Herbert Y.

AU - Potkin, Steven G.

AU - Niedling, Charlotte

AU - Steimer, Werner

AU - Leucht, Stefan

AU - Knight, Jo

AU - Müller, Daniel J.

AU - Kennedy, James L.

PY - 2015/1

Y1 - 2015/1

N2 - AIM: TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain.PATIENTS & METHODS: We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119).RESULTS: TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10(-3)), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10(-3)) and RUPP samples (p = 2.76 × 10(-4)).CONCLUSION: Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect.

AB - AIM: TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain.PATIENTS & METHODS: We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119).RESULTS: TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10(-3)), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10(-3)) and RUPP samples (p = 2.76 × 10(-4)).CONCLUSION: Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect.

KW - Adolescent

KW - Adult

KW - Antipsychotic Agents

KW - Female

KW - Genetic Association Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Receptors, GABA

KW - Schizophrenia

KW - Treatment Outcome

KW - Weight Gain

U2 - 10.2217/pgs.14.158

DO - 10.2217/pgs.14.158

M3 - Journal article

C2 - 25560467

VL - 16

SP - 5

EP - 22

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 1

ER -